| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.7 | 0.01 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.01 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.085 | 0.02 |